Mitochon Pharmaceuticals
Mitochon Pharmaceuticals is a clinical-stage biotech company focused on developing drugs that target mitochondrial dysfunction to treat serious neurodegenerative and neuromuscular diseases. Their mission is to create meaningful therapies that modulate mitochondrial physiology to slow disease progression and improve patient outcomes. Mitochon aims to open the door for a broad range of disease-modifying therapies by correcting mitochondrial dysfunctions linked to various diseases.
Patents
Induced expression of brain derived neurotrophic factor (BDNF) for treatment of neuromuscular, neurodegenerative, autoimmune, developmental and/or metabolic diseases
2023-08-08 • US-11717497-B2
View DetailsDNP and DNP prodrug treatment of neuromuscular, neurodegenerative, autoimmune, developmental, traumatic brain injury, concussion, dry eye disease, hearing loss and/or metabolic diseases
2022-08-09 • US-11406642-B2
View DetailsInduced expression of brain derived neurotrophic factor (BDNF) for treatment of neuromuscular, neurodegenerative, autoimmune, developmental and/or metabolic diseases
2020-12-15 • US-10864173-B2
View DetailsDNP and DNP prodrug treatment of neuromuscular, neurodegenerative, autoimmune, developmental, traumatic brain injury, concussion, dry eye disease, hearing loss and/or metabolic diseases
2020-02-04 • US-10548900-B2
View DetailsInduced expression of brain derived neurotrophic factor (BDNF) for treatment of Neuromuscular, neurodegenerative, autoimmune, developmental and/or metabolic diseases
2019-03-05 • US-10220006-B2
View DetailsInduced expression of brain derived neurotrophic factor (BDNF) for treatment of neuromuscular, neurodegenerative, autoimmune, developmental and/or metabolic diseases
2018-05-22 • US-9974755-B2
View DetailsWhat We Do
Digital Health Technologies
Services
Diagnostics
Biologics
Key People
Founder & CEO
Founder & Chief Scientific Officer
Acting Chief Medical Officer
News & Updates
Research published on November 18, 2024, demonstrating the efficacy of micro-doses of DNP in ALS models.
Announcement on January 9, 2024, regarding the initiation of a biomarker study for neurodegenerative diseases.
Announcement on August 21, 2023, about a research award for MP-201.
Announcement on May 8, 2023, regarding a research grant for glaucoma.
An article discussing the potential of Mitochon’s drugs in treating traumatic brain injuries, published on May 6, 2024.
An article published on April 4, 2023, discussing Mitochon’s approach to neurodegeneration and aging.